Overview

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

Status:
Terminated
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate an investigational drug (Tolcapone) alone and in combination with oxaliplatin, for relapsed and refractory neuroblastoma. Tolcapone is approved by the U.S. Food and Drug Administration (FDA) for adults, but is an investigational drug in this study because it has not been approved in pediatrics for this indication. Oxaliplatin, although a drug approved by the FDA for other cancers, is investigational for treatment of neuroblastoma in this study. This study will look at the safety and tolerability of tolcapone in combination with oxaliplatin as well as the tumors response to this study drug.
Phase:
Phase 1
Details
Lead Sponsor:
Giselle SaulnierSholler
Spectrum Health Hospitals
Treatments:
Oxaliplatin
Tolcapone